"New era for UK diagnostics' BIVDA (British In vitro Diagnostics Association)":
This article was originally published in Clinica
Executive Summary
The British In vitro Diagnostics Association (BIVDA) has appointed William Burns as president for a three-year term, in a move that is being branded as the beginning of a new era for the sector's leading voice in the UK. Mr Burns, with over 25 years' experience in the IVDs sector, including as president of the European Diagnostic Manufacturers Association (EDMA), replaces Brian Fishwick. "My wish as president of BIVDA is to truly establish the value of diagnostics and to ensure these advances benefit patients in the healthcare continuum," said Mr Burns, who is retiring from Ortho-Clinical Diagnostics, where he has been vice-president, international, for six years.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.